Korro Bio, Inc. developed the OPERA platform using an RNA editing oligonucleotide to recruit the endogenous ADAR enzyme to messenger RNA for single-base A-to-I RNA editing.
Public source
Publisher name
Public post
Human cells have a natural ability to modify single “alphabets" on RNA, a process known as #RNAediting. One such process utilizes an enzyme called ADAR, inside the cells…
Company
Korro Bio, Inc.
Edit the message. Rewrite the future. Pioneering RNA editing to deliver the future of medicine.
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 51–200 employees
About Korro Bio, Inc.
Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Products & Services
Vico Therapeutics
Vico Therapeutics is developing RNA-targeted therapies designed to address the shared genetic mutation in polyglutamine diseases.
Products & Services
EditCo Bio
EditCo Bio launched an automated CRISPR platform designed to handle scale work by building and validating cell models across genes, cell backgrounds, and experimental conditions.
Products & Services
Integrated DNA Technologies
Integrated DNA Technologies developed UNCOVERseq™ to provide a more sensitive, reproducible, and standardized approach to off-target nomination for CRISPR-based therapies.
Products & Services
Serna Bio
Serna Bio built and tested its platform over the past five years across internal programs and commercial partners.
Products & Services
Moonwalk Biosciences